Shanghai Junshi Biosciences Co Ltd (688180) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Junshi Biosciences Co Ltd (688180) has a cash flow conversion efficiency ratio of -0.023x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-142.12 Million ≈ $-20.80 Million USD) by net assets (CN¥6.22 Billion ≈ $910.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688180 stock market capitalisation for the company's overall valuation and market capitalisation.
Shanghai Junshi Biosciences Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Shanghai Junshi Biosciences Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Junshi Biosciences Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Junshi Biosciences Co Ltd ranked by their cash flow conversion efficiency. Explore Shanghai Junshi Biosciences Co Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bath & Body Works Inc.
NYSE:BBWI
|
-0.068x |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
0.190x |
|
ASSECO POLAND GDR/1 ZY 1
F:SFBG
|
N/A |
|
Hangzhou Binjiang Real Estate Group Co Ltd
SHE:002244
|
0.019x |
|
Valvoline Inc
NYSE:VVV
|
0.270x |
|
Union Semiconductor (Hefei) Co. Ltd. A
SHG:688403
|
N/A |
|
Asbury Automotive Group Inc
NYSE:ABG
|
0.057x |
|
Brady Corporation
NYSE:BRC
|
0.058x |
Annual Cash Flow Conversion Efficiency for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. View current stock price of Shanghai Junshi Biosciences Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.22 Billion ≈ $910.73 Million |
CN¥-478.14 Million ≈ $-69.97 Million |
-0.077x | +68.32% |
| 2024-12-31 | CN¥5.95 Billion ≈ $870.71 Million |
CN¥-1.44 Billion ≈ $-211.13 Million |
-0.242x | +11.46% |
| 2023-12-31 | CN¥7.32 Billion ≈ $1.07 Billion |
CN¥-2.00 Billion ≈ $-293.39 Million |
-0.274x | -51.10% |
| 2022-12-31 | CN¥9.79 Billion ≈ $1.43 Billion |
CN¥-1.78 Billion ≈ $-259.79 Million |
-0.181x | -135.29% |
| 2021-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
CN¥-641.90 Million ≈ $-93.93 Million |
-0.077x | +69.98% |
| 2020-12-31 | CN¥5.84 Billion ≈ $854.76 Million |
CN¥-1.50 Billion ≈ $-219.32 Million |
-0.257x | +35.40% |
| 2019-12-31 | CN¥2.99 Billion ≈ $437.31 Million |
CN¥-1.19 Billion ≈ $-173.70 Million |
-0.397x | -158.27% |
| 2018-12-31 | CN¥3.32 Billion ≈ $485.99 Million |
CN¥-510.76 Million ≈ $-74.74 Million |
-0.154x | +50.40% |
| 2017-12-31 | CN¥1.12 Billion ≈ $163.79 Million |
CN¥-347.08 Million ≈ $-50.79 Million |
-0.310x | -88.62% |
| 2016-12-31 | CN¥1.13 Billion ≈ $164.86 Million |
CN¥-185.21 Million ≈ $-27.10 Million |
-0.164x | -23.10% |
| 2015-12-31 | CN¥614.22 Million ≈ $89.88 Million |
CN¥-82.03 Million ≈ $-12.00 Million |
-0.134x | -9.00% |
| 2014-12-31 | CN¥319.87 Million ≈ $46.81 Million |
CN¥-39.19 Million ≈ $-5.73 Million |
-0.123x | -- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more